JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
- Sunday, September 26, 2021, 7:14
- Environment
- Add a comment
SHANGHAI, Sept. 26, 2021 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection…
About the Author
adminasapcorp has written 39095 stories on this site.